FY 2025-26 Highlights

Momentum Built
on Capability

Financial

6,813 crore
Revenue from operations
23%
1,826 crore
EBITDA
64%
26.8 %
EBITDA margin
6.7% bps
889 crore
Profit after tax
148%
14.6 %
Dividend payout ratio
y-o-y growth
17.7 %
Return on capital employed
8% pp

Operational

Advancing Peptides development & manufacturing infrastructure in Vizag to support fully integrated programmes

Established Gene therapy / ADC process development lab in Hyderabad

Accelerating greenfield capacity creation for microbial fermentation in Vizag

Completed 132 Quality audits in FY 2025-26 Company has successfully passed audit inspections without critical findings

ESG

Achieved a Global Corporate Sustainability Assessment (CSA) & ESG score of 81 out of 100 points, an impressive 8 points increase over the last year

Consecutive Four Years’ MSCI “BBB” Rating (as on September 2025), S&P Global Sustainability Yearbook 2026 member from Pharma industry

Commenced process of establishing GHG targets aligned with SBTi standards

1,17,375 GJ
Energy consumed from renewable sources
3,42,862 KL
Water recycled or reused
9 %
Female employees
0
Man-hours spent on health and safety training
50 %
Independent Directors
20 %
Women Directors